ClinicalTrials.gg
RecruitingNCT06249867Updated Oct 9, 2026

A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

A Phase 2 interventional study of Darifenacin 7.5 MG Extended Release Oral Tablet and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Oliver Blanchard. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Oliver Blanchard · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 9, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
44th of 72
60 · median 75
Started
2024
with 8 others
Phase 2
21 of 82
2 open now
Primary completion
2027-10
later than 15 of 24 live
Registered
68th of 82
by date

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 44th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2024, is one of 21 in phase 2, reaches primary completion later than 15 of the 24 other live ones, and was the 68th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder characterized by selective death of upper and lower motor neurons, which leads to severe disability and fatal outcomes. One of the major hallmarks of ALS is the denervation of neuromuscular junctions (NMJs), which is one of the earliest events seen in ALS patients and mouse models of ALS. Under healthy conditions, glial cells called Perisynaptic Schwann Cells (PSCs) have a key role in regulating the stability and maintenance of NMJs, but they only participate in NMJ repair once denervation occurs. Denervation and the subsequent decline in synaptic activity triggers a loss of muscarinic acetylcholine receptors (mAChRs) in the PSC, and the resulting decrease in mAChR-mediated gene expression drives the "repair mode" of the PSC. In assessing the NMJ under conditions of ALS, a scarcity of process extensions in PSCs was observed for months prior to disease onset in the superoxide dismutase 1 (SOD1) mouse model of ALS, indicating inadequate glial repair. Collectively, these preclinical findings support the hypothesis that dampening glial mAChRs will restore the anticipated "repair" response of PSCs in the NMJ. Hence, the use of a selective M3 muscarinic receptor antagonist, Darifenacin, as a disease-modifying therapeutic in familial and sporadic ALS could improve NMJ function, resulting in a beneficial impact on the autonomy and quality of life of ALS patients.

The purpose of the current Phase 2 trial is therefore to test the safety, tolerability, and pharmacology of Darifenacin in patients with ALS. Specifically, 60 eligible subjects between 18 and 85 years of age will take 7.5 mg of darifenacin or placebo daily (by mouth) for two weeks followed by an increased dose of 15 mg for the next 22 weeks. The trial will evaluate the effects of this medication on several outcome measures including patient safety, physical and neurological function, muscle strength, depression levels, and NMJ innervation of patients with ALS. Detailed clinical assessments will be conducted at regular intervals throughout the study in order to achieve these objectives.

Read the detailed description

ALS is a rapidly progressive neurodegenerative disorder caused by the selective death of motor neurons within the brain, brainstem, and spinal cord, leading to paralysis and death within 2-5 years after diagnosis. A limited number of disease-modifying treatments are available for patients with ALS, namely Riluzole (Rilutek), Edaravone (Radicava), and AMX0035 (Relyvrio in the USA and Albrioza in Canada), and novel therapeutic approaches are being investigated to tackle several aspects of ALS pathological features.

One of the major hallmarks of ALS is the denervation of neuromuscular junctions (NMJs), which is one of the earliest events seen in ALS patients and murine models that recapitulate ALS-like aspects of the disease due to ALS-causing mutations in the SOD1, TDP-43, and FUS genes. It has been shown that an extensive and extended period of NMJ denervation-reinnervation cycles occurs months prior to disease onset in SOD1 ALS mice. To be specific, scarce Perisynaptic Schwann Cell (PSC) process extensions were observed, which indicates inadequate glial repair. Therefore, while PSCs are responsive to NMJ alterations in ALS, their response does not support NMJ repair. PSCs have a key role in regulating the stability and maintenance of NMJs. They actively participate in NMJ repair once denervation and loss of muscarinic acetylcholine receptors (mAChRs) occur. Additionally, regulation of PSC gene expression, governed by mAChR activation, drives the dynamic adaptation of the PSC in a synaptic activity-dependent manner. PSCs will switch to a repair mode when mAChR activation is reduced, such as following a sciatic nerve crush injury and during synapse formation.

Collectively, these preclinical findings support the hypothesis that dampening glial mAChRs will restore the anticipated "repair" response of PSCs in the NMJ. Hence, the use of a selective M3 muscarinic receptor antagonist, Darifenacin, as a disease-modifying therapeutic in familial and sporadic ALS could improve NMJ function, resulting in a beneficial impact on the autonomy and quality of life of ALS patients. The purpose of the current Phase 2 trial is therefore to test the safety, tolerability, and pharmacology of Darifenacin in patients with ALS.

ENABLEX (Darifenacin Extended Release Tablets), or darifenacin hydrobromide, is a known active substance with the chemical name: (S)-2-{1-[2-(2,3-Dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidnyl}-2,2-diphenylacetamide hydrobromide. Darifenacin will be produced and formulated into 7.5 mg coated tablets (extended-release) by Searchlight Pharma and a placebo film-coated tablet will be manufactured without the active substance by Apotex Inc.

Patient enrollment for this trial will consist of 60 eligible ALS patients between 18 and 85 years of age. During the first \~two weeks (titration period), patients will receive a daily dose of either a placebo or a 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together. Depending on the patient's response to the medication, they may be asked to temporarily or permanently stop taking the drug or reduce their dose from 15 mg to 7.5 mg for safety reasons. This treatment period has been selected as a standard for phase 2 trials to study the endpoints and observe significant differences in the outcome measures.

The trial will evaluate the effects of this medication and dosing regimen on several outcome measures including patient safety, physical and neurological function, muscle strength, depression levels, and NMJ innervation of patients with ALS. Detailed clinical assessments will be conducted at regular intervals throughout the study in order to achieve these objectives.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Amyotrophic lateral sclerosis
  • Darifenacin
  • Neuromuscular junction
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to comprehend and willing to sign an Form (ICF).
  2. Male or female, ≥ 18 years old and ≤85 years old, at the time of signing the ICF.
  3. Confirmed diagnosis of familial or sporadic ALS, defined as meeting the probable, laboratory-supported probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology Modified El Escorial criteria (1).
  4. ALS duration of less than 36 months from the symptom onset.
  5. FVC of ≥ 50 %.
  6. Able to swallow tablets without crushing.
  7. A female patient is eligible to participate if she is not breastfeeding, has negative pregnancy test at screening, has no intention of becoming pregnant during the course of the study, and agrees to use appropriate drugs or devices (as defined in section 3.4 of the study protocol) for the duration of the study.
  8. If male and has a partner who may become pregnant, agrees to ensure that he and/or his partner use a reliable form of birth control (as defined in section 3.4 of the study protocol) for the duration of the study and refrain from donating sperm during this period.
  9. Participants receiving standard care for ALS prior to entering the trial (i.e. Riluzole, Edaravone, and Albrioza), must be on a stable dosing regimen prior to the randomization and agree to remain on this dosage during the study period:

    • In the case of taking Riluzole, the patient must have been on a stable dose at least 30 days prior to start date.
    • In the case of taking Edaravone, the patient must have been on a stable dose at least 30 days prior to start date.
    • In the case of receiving Albrioza, the patient must have been on a stable dose at least 30 days prior to start date.
  10. For participants who consent to the optional :

    • Participants with normal or coagulation test values.
    • Participants who are receiving anticoagulant medications will need to abstain from using anticoagulants for a specific number of days before and after the biopsy, as decided by the study doctor on a case-by-case basis.

Exclusion criteria

Exclusion Criteria:

  1. Patients with, or at risk for, the following conditions:

    • Untreated or uncontrolled narrow-angle glaucoma;
    • Gastric retention
    • Urinary retention
    • Liver disease
  2. Patients with a known history of severe allergic or anaphylactic reactions to antimuscarinic medications
  3. If diagnosed with another neurodegenerative disease (e.g. Multiple Sclerosis, Parkinson, Myasthenia Gravis, and Alzheimer's disease).
  4. Subjects with severe hepatic impairment or abnormal liver enzymes, as defined as B and C scores.
  5. Subject has a history of, or positive test result at Screening, for virus antibody.
  6. Subjects with acute or prolonged \& C.
  7. Any medical condition that might interfere with the patient's participation in the trial, poses any added risk for the patient, or confounds the assessment of the patient according to the Investigator's judgement.
  8. Subjects with any uncontrolled (unresolved) medical condition other than ALS, as determined by the Investigator.
  9. Subjects who are currently enrolled in another clinical trial and receiving an Product (IP) (including but not limited to stem cell therapy or gene therapy).
  10. Treatment with an investigational drug within 1 month or within a time period equal to 5 half-lives (if known) whichever is longer, of starting study treatment.
  11. Patients with prior darifenacin treatment.
  12. History of drug and/or alcohol abuse (according to ) prior to the screening as determined by the Investigator.
  13. If female, subjects who are pregnant, breastfeeding, or intending to conceive during the course of the study.
  14. Subjects with an abnormal (ECG) at screening (any abnormality that the PI believes that entering the study place the participant at risk).
  15. Subjects who are receiving strong inducers such as carbamazepine (anticonvulsant), phenytoin (anticonvulsant), rifampin (antibiotic), and modafinil (wakefulness-promoting agent).
  16. Subjects who are receiving potent CYP3A4 inhibitors such as clarithromycin (macrolide antibiotic), ketoconazole and itraconazole (antifungal medications), nefazadone (antidepressant), nelfinavir and ritonavir (protease inhibitors).
  17. Subjects who are receiving or received within 30 days prior to the starting of the trial CYP2D6 substrates with a narrow therapeutic window such as include flecainide (Class IC anti-arrhythmic), thioridazine (antipsychotic) and tricyclic antidepressants.
  18. Subjects who are receiving or received intramuscular botulinum injections in the arms, legs, or face in the past 6 months.
  19. Subjects who are receiving or received within 30 days prior to the starting of the trial antimuscarinic medications for the treatment of overactive bladder such as fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium.
  20. Only for patients that consented to the Optional Needle Muscle procedures.
  21. Subject is taking an anticoagulant (with the exception of aspirin at the investigator's discretion) or is at risk of increased or uncontrolled muscle biopsy-related bleeding.
  22. Subjects with bleeding risk factors which include, but are not limited to, anatomical factors at or near the muscle biopsy site (e.g., vascular abnormalities, neoplasms, or other abnormalities) or abnormal or coagulation test values at visit 1.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Darifenacin Treatment

    Patients in the Treatment arm will receive a daily dose of 1 or 2 darifenacin extended-release tablets.

    Drug: Darifenacin 7.5 MG Extended Release Oral Tablet

  • Placebo comparator
    Placebo

    Patients in the Placebo arm will receive a daily dose of 1 or 2 placebo tablets.

    Drug: Placebo

Interventions

  • DrugDarifenacinStudies of DarifenacinDarifenacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    During the first \~two weeks (titration period), patients in the treatment arm will receive a daily dose of 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together for a period of 22 weeks.

    Also known as: Darifenacin

  • DrugPlacebo

    During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of oral doses of 15 mg darifenacin

    The incidence of adverse events and any abnormal clinical assessments will be monitored.

    Time frame: 24 weeks

Secondary outcomes

  1. Pharmacokinetics of oral doses of darifenacin

    The pharmacokinetic profile of darifenacin in ALS patients will be visualized at Day 1, 14, and 28.

    Time frame: 4 weeks

  2. Electrical Impedance Myography (EIM)

    EIM is a non-invasive technique that measures the electrical impedance characteristics of specific muscles or muscle groups as a readout of muscle health.

    Time frame: 24 weeks

  3. Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score

    The ALSFRS-R will be used to measure activities of daily living (ADL) and global function across four domains (respiratory, bulbar function, gross motor skills, and fine motor skills) and consists of 12 questions, each scored from 0 to 4, for a total possible score of 48, with higher scores representing better function.

    Time frame: 24 weeks

  4. Forced Vital Capacity (FVC)

    The FVC test examines lung capacity and overall respiratory function.

    Time frame: 24 weeks

  5. King's College (KINGS) stage

    The KINGS staging system for ALS will be used to assess the course of the disease and is based on the number of involved regions (where the three possible regions are bulbar, upper limb or lower limb) for the first three stages and the need for gastrostomy and non-invasive ventilation for the subsequent stages. The possible stages in the KINGS staging system are as follows: Stage 1: First Region Involved; Stage 2: Second Region Involved; Stage 3: Third Region Involved; Stage 4a: Nutritional Failure (need for gastrostomy); Stage 4b: Respiratory Failure (need for non-invasive ventilation); and Stage 5: Death.

    Time frame: 24 weeks

  6. Hand-Held Dynamometry (HHD)

    HHD will be used to examine muscle strength in various muscles of the arms and legs.

    Time frame: 24 weeks

  7. ALS Assessment Questionnaire (ALSAQ5)

    The ALSAQ-5 is one of the most widely validated measures of health status for use with patients diagnosed with ALS. This questionnaire evaluates 5 subdimensions: mobility, ADL, eating and drinking, communication, and emotional functioning.

    Time frame: 24 weeks

Other outcomes

  1. Depression and depressive symptoms

    The self-administered Patient Health Questionnaire (PHQ-9) will be used to assess depressive symptoms.

    Time frame: 24 weeks

  2. Physical function and daily activities

    The self-administered the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) questionnaire will assess levels of overall disability in patients.

    Time frame: 24 weeks

  3. Neuromuscular junction innervation

    Neuromuscular junctions (NMJs) will be functionally and visually examined to monitor the effect of darifenacin.

    Time frame: 24 weeks

  4. Pharmacodynamics of oral doses of 15 mg darifenacin

    Blood-based biomarkers will be examined on Day 1, 14, 28, and 168 to determine the pharmacodynamic profile of darifenacin in ALS patients.

    Time frame: 24 weeks

07

Study locations

2 of 2 sites recruiting
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1Y 4E9, Canada
    Recruiting
    • Isabel Horton · Contactihorton@ohri.ca · 613-798-5555
    • Ariel Breiner, MD · Principal investigator
    • Jocelyn Zwicker · Sub investigator
  • Montreal Neurological Institute
    Montreal, Quebec H3A 2B4, Canada
    Recruiting
    • Jessica Cuerquis · Contactjessica.cuerquis@mcgill.ca · 514-396-1023
    • Oliver Blanchard, MD CM, FRCPC · Principal investigator
    • Angela Genge, MD, FRCPC · Sub investigator
    • Rami Massie, MD · Sub investigator
08

References and documents

Publications

  • Moss KR, Darvishi FB, Badawi Y, Fish LA, Funke JR, Pedersen TH, Robitaille R, Arnold WD, Burgess RW, Meriney SD, Nishimune H, Saxena S. The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease. J Neurosci. 2025 Nov 12;45(46):e1353252025. doi: 10.1523/JNEUROSCI.1353-25.2025. PubMed 41224659 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.

Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's planned 35 months is close to that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Aug 2027 → Oct 2027 and completion Sep 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 8, 2024
StartActual
Nov 8, 2024
Primary completionEst.
Oct 2027was Aug 2027
CompletionEst.
Nov 2027was Sep 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2027→Oct 2027
Oct 9, 2026
Study completion
Sep 2027→Nov 2027
Oct 9, 2026
Enrollment
30→60
Oct 9, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedSubjects who are receiving or received intramuscular botulinum injections in the arms, legs, or face in the past 6 months.
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Aug 2027→Oct 2027
    Study completion Sep 2027→Nov 2027
    Enrollment 30→60
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedSubjects who are receiving or received intramuscular botulinum injections in the arms, legs, or face in the past 6 months.
    + 5 other changes: identifiers, verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06249867
Lead sponsor
Oliver Blanchard
Collaborators
Université de Montréal
Responsible party
Oliver Blanchard (Assistant Professor, McGill University) — Sponsor-investigator
First posted
Feb 8, 2024
Start date
Nov 8, 2024
Primary completion
Oct 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Nisha Pulimood, PhD
Contact
nisha.pulimood@mcgill.ca
514-396-2401
Gabriele Riva, PhD
Contact
gabriele.riva@mcgill.ca
Oliver Blanchard, MD
principal investigator · McGill University - Montreal Neurological Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darifenacin

Start the discussion